INmune Bio (INMB) Competitors $7.74 -0.12 (-1.50%) As of 12:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INMB vs. AVBP, LENZ, EOLS, DNTH, ANAB, XERS, ABUS, CDXC, ARVN, and KALVShould you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include ArriVent BioPharma (AVBP), LENZ Therapeutics (LENZ), Evolus (EOLS), Dianthus Therapeutics (DNTH), AnaptysBio (ANAB), Xeris Biopharma (XERS), Arbutus Biopharma (ABUS), ChromaDex (CDXC), Arvinas (ARVN), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. INmune Bio vs. ArriVent BioPharma LENZ Therapeutics Evolus Dianthus Therapeutics AnaptysBio Xeris Biopharma Arbutus Biopharma ChromaDex Arvinas KalVista Pharmaceuticals ArriVent BioPharma (NASDAQ:AVBP) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, community ranking, risk, profitability, media sentiment, analyst recommendations and institutional ownership. Does the MarketBeat Community believe in AVBP or INMB? INmune Bio received 123 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 76.60% of users gave INmune Bio an outperform vote. CompanyUnderperformOutperformArriVent BioPharmaOutperform Votes21100.00% Underperform VotesNo VotesINmune BioOutperform Votes14476.60% Underperform Votes4423.40% Is AVBP or INMB more profitable? ArriVent BioPharma's return on equity of -43.89% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets ArriVent BioPharmaN/A -43.89% -29.67% INmune Bio N/A -117.48%-78.96% Do analysts rate AVBP or INMB? ArriVent BioPharma currently has a consensus target price of $39.00, suggesting a potential upside of 85.27%. INmune Bio has a consensus target price of $22.80, suggesting a potential upside of 194.50%. Given INmune Bio's higher probable upside, analysts plainly believe INmune Bio is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17INmune Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the media favor AVBP or INMB? In the previous week, ArriVent BioPharma had 2 more articles in the media than INmune Bio. MarketBeat recorded 6 mentions for ArriVent BioPharma and 4 mentions for INmune Bio. INmune Bio's average media sentiment score of 1.47 beat ArriVent BioPharma's score of 0.54 indicating that INmune Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive INmune Bio 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of AVBP or INMB? 9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 35.2% of INmune Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation and earnings, AVBP or INMB? INmune Bio has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArriVent BioPharmaN/AN/A-$69.33M-$2.57-8.19INmune Bio$14K12,710.15-$30.01M-$2.11-3.67 Which has more risk & volatility, AVBP or INMB? ArriVent BioPharma has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, INmune Bio has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. SummaryINmune Bio beats ArriVent BioPharma on 10 of the 14 factors compared between the two stocks. Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INMB vs. The Competition Export to ExcelMetricINmune BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$176.52M$2.96B$5.49B$7.97BDividend YieldN/A1.89%5.11%4.23%P/E Ratio-3.5230.2622.6118.58Price / Sales12,710.15494.29397.51103.15Price / CashN/A168.6838.1834.62Price / Book3.743.166.704.26Net Income-$30.01M-$72.35M$3.22B$248.31M7 Day Performance-3.71%0.81%1.26%1.34%1 Month Performance2.00%8.04%3.73%3.92%1 Year Performance-33.26%-22.95%15.82%5.33% INmune Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMBINmune Bio2.3449 of 5 stars$7.74-1.5%$22.80+194.5%-33.6%$176.52M$14,000.00-3.5210Upcoming EarningsNews CoveragePositive NewsAVBPArriVent BioPharma1.0395 of 5 stars$19.54+7.7%$39.00+99.6%+28.7%$664.67MN/A-7.6040Short Interest ↑News CoveragePositive NewsLENZLENZ Therapeutics1.9507 of 5 stars$24.11+1.2%$46.60+93.3%+79.6%$664.06MN/A-5.05110EOLSEvolus3.8493 of 5 stars$10.38-3.8%$23.75+128.8%-3.1%$660.03M$266.27M-11.41170Upcoming EarningsNews CoverageDNTHDianthus Therapeutics1.7382 of 5 stars$20.45+4.9%$54.33+165.7%+2.3%$656.98M$6.24M-8.1880Upcoming EarningsNews CoveragePositive NewsANABAnaptysBio2.5266 of 5 stars$20.62+0.3%$33.63+63.1%-8.7%$632.35M$91.28M-3.39100Upcoming EarningsNews CoveragePositive NewsXERSXeris Biopharma3.5779 of 5 stars$4.02-2.2%$6.10+51.7%+161.1%$618.84M$203.07M-8.93290Upcoming EarningsNews CoveragePositive NewsABUSArbutus Biopharma2.0068 of 5 stars$3.21+1.9%$5.50+71.3%+30.0%$614.65M$6.17M-7.4690CDXCChromaDex2.3375 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120Upcoming EarningsAnalyst ForecastARVNArvinas3.3962 of 5 stars$8.75+1.7%$34.33+292.4%-69.7%$601.76M$263.40M-3.16420Earnings ReportShort Interest ↑News CoverageHigh Trading VolumeKALVKalVista Pharmaceuticals4.38 of 5 stars$12.01+0.1%$24.83+106.8%+21.3%$597.09MN/A-3.30100Positive News Related Companies and Tools Related Companies ArriVent BioPharma Competitors LENZ Therapeutics Competitors Evolus Competitors Dianthus Therapeutics Competitors AnaptysBio Competitors Xeris Biopharma Competitors Arbutus Biopharma Competitors ChromaDex Competitors Arvinas Competitors KalVista Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INMB) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INMB Stock Free INMB Stock Alerts